vTv Therapeutics (VTVT) Net Income towards Common Stockholders (2014 - 2026)

vTv Therapeutics (VTVT) has 13 years of Net Income towards Common Stockholders data on file, last reported at $24.1 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders rose 573.96% year-over-year to $24.1 million; the trailing twelve-month figure through Mar 2026 stood at $2.3 million (up 112.05% YoY), and the FY2025 full-year result was -$27.0 million, down 46.11% from the prior year.
• Net Income towards Common Stockholders climbed to $24.1 million in Q1 2026, from -$7.1 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $24.1 million in Q1 2026 to a low of -$8.7 million in Q3 2025.
• A 5-year average of -$3.6 million and a median of -$4.9 million in 2024 frame the typical range for Net Income towards Common Stockholders.
• Across the five-year window, Net Income towards Common Stockholders plunged 418.26% in 2022 and soared 573.96% in 2026, its largest moves.
• Tracing VTVT's Net Income towards Common Stockholders over 5 years: stood at -$4.7 million in 2022, then gained by 26.7% to -$3.5 million in 2023, then decreased by 4.49% to -$3.6 million in 2024, then tumbled by 96.42% to -$7.1 million in 2025, then soared by 438.11% to $24.1 million in 2026.
• Business Quant data shows VTVT's Net Income towards Common Stockholders at $24.1 million in Q1 2026, -$7.1 million in Q4 2025, and -$8.7 million in Q3 2025.